Related Experiment Video
Updated: Aug 5, 2026
12:43
Rodent Working Heart Model for the Study of Myocardial Performance and Oxygen Consumption
Published on: August 16, 2016
Vasodilation through levodopa for Parkinson's disease may require high left ventricular assist device flow
Corstiaan A den Uil1,2, Edith C H Friesema3, Alina A Constantinescu1
1Department of Cardiology, Mechanical Circulatory Support and Cardiac Transplantation, University Medical Center, Thoraxcenter, Erasmus University Medical Center, Rotterdam, the Netherlands.
Journal of Cardiac Surgery
|March 9, 2019
Summary
This study details a left ventricular assist device (LVAD) implantation in a Parkinson's patient, highlighting potential kidney injury due to fluid overload and medication side effects. Early optimization of LVAD function is crucial for patient recovery.
Area of Science:
- Cardiology
- Nephrology
- Neurology
Background:
- Left ventricular assist device (LVAD) implantation is a critical intervention for advanced heart failure.
- Parkinson's disease presents unique challenges in managing patients with cardiac conditions.
- Levodopa, a common Parkinson's medication, can cause vasodilation, impacting hemodynamics.
Observation:
- A patient with Parkinson's disease underwent LVAD implantation.
- Postoperative period was complicated by fluid overload and vasodilation.
- These factors led to reduced LVAD output and renal hypoperfusion.
Findings:
- Acute kidney injury (AKI) developed in the setting of fluid overload and levodopa-induced vasodilation.
- Insufficient LVAD output contributed to the renal complications.
- The interplay between Parkinson's disease medication and LVAD function was observed.
Implications:
- Careful hemodynamic management is essential in Parkinson's patients with LVADs.
- Early and aggressive optimization of LVAD parameters (e.g., HM3 RPM, flow) is critical.
- This case underscores the need for tailored postoperative care strategies in complex patient populations.
Related Concept Videos
01:26Heart Failure Drugs: Inotropic Agents
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
01:24Parkinson's Disease: Treatment
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
01:30Heart Failure V: Medical Management
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
01:22Heart Failure VI: Adjunct Therapies
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
01:30Cardiomyopathy II: Dilated Cardiomyopathy
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
01:29Cardiomyopathy V: Interprofessional Care
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...